Preclinical FLCN-deficient mouse models demonstrated activation of AKT-mTOR pathway, with the mTOR inhibitor rapamycin halting renal cyst and tumor growth in these animals [209,210]. This evidence concerns the gene MTOR and cystic kidney disease.